Literature DB >> 25029320

Toxic interaction between Th2 cytokines and Staphylococcus aureus in atopic dermatitis.

Jeffrey B Travers1.   

Abstract

Patients with atopic dermatitis (AD) are commonly colonized/infected with Staphylococcus aureus, and this bacterium is known to worsen the dermatitis. In this issue, Brauweiler et al. demonstrate a newly discovered mechanism by which Th2 cytokines involved in AD augment the toxicity of the lytic staphylococcal protein alpha toxin. This review presents mechanisms by which Th2 cytokines may interact with S. aureus to the detriment of the dermatitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25029320      PMCID: PMC4101911          DOI: 10.1038/jid.2014.122

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


The vast majority (~90%) of individuals with active atopic dermatitis (AD) are colonized/infected with Staphylococcus aureus, a species implicated in worsening the skin disease. The propensity of these patients to harbor staphylococcal bacteria is thought to be due in part to the inhibitory effects of Th2 cytokines (IL-4, IL-13) on antimicrobial peptide production. Through this mechanism and the inhibitory effects of these cytokines on barrier formation, Th2 cytokines provide an environment conducive to bacterial growth. Given their clinical importance in the management of AD, the mechanisms by which staphylococcal bacteria worsen AD are areas of active study. Staphylococcal bacteria trigger inflammation from direct infection of cell types such as keratinocytes. Staphylococcal products can also exert profound effects via binding to specific receptors. With examples listed in Table I, these agents include exotoxins that act as superantigens, staphylococcal protein A, the cell wall product lipoteichoic acid, and cytolytic toxins such as staphylococcal alpha toxin and delta toxin. The exact importance of these staphylococcal products in AD associated with infection is, as yet, unknown.
Table I

Mechanisms by which staphylococcal products can modulate AD and role of Th2 cytokines.

Staphylococcal MediatorEffect on AD Skin LesionTh2 cytokine effectReferences
Alpha toxinIncreased keratinocyte cell death and worsening of lesion; increased cytokine productionIncreased toxicity via inhibiting filaggrin, acid sphingomyelinaseBrauweiler et al., 2013, 2014
Delta toxinIncreased mast cell degranulation and worsening of lesionIncreased effect via increased IgE productionNakamura et al., 2013
Superantigen (SEB, TSST-1…)Increased mast cell degranulation and release of cytokines via triggering specific IgE molecules and worsening of lesionIncreased effect via increased IgE productionLeung et al., 1993
Staphylococcal Protein AUnclear effects; Increased inflammation via signaling through TNFR1 versus anti-inflammatory effects via removal of TNF-αNot knownGiai et al., 2013
Lipoteichoic acidIncreased inflammation via signaling through TLR2 and Platelet-activating factor receptor and worsening of lesionNot knownTravers et al., 2010
Superantigens including Toxic Shock Syndrome Toxin-1 (TSST-1) and Staphylococcal enterotoxin B (SEB) have significant pro-inflammatory effects via their abilities to bind to MHCII molecules and activate large numbers of T cells. Relevant to AD, many patients harbor specific IgE antibodies that recognize these large globular proteins (Leung ). Thus, superantigen-producing S. aureus could generate type I allergic responses via this mechanism. Staphylococcal Protein A (SPA), a surface protein, acts as an important, yet complex, virulence factor contributing to the success of this pathogen by interfering with immune clearance and by modulating inflammation in part via its ability to activate the TNF receptor 1 (TNFR1) directly. Although this would be expected to engender a pro-inflammatory response, recent studies have suggested that through triggering of TNFR1 shedding, SPA can actually exert anti-inflammatory effects by the removal of local TNF-α (Giai ). The cell wall component lipoteichoic acid (LTA) has also been implicated in AD inflammation. Recent studies indicate that large (microgram) amounts of this toll-like receptor 2- and Platelet-activating factor receptor agonist are found on the skin of children with secondarily infected AD (Travers ). Staphylococcal bacteria also commonly express at least four cytolytic toxins that appear to play important roles in virulence as well as in host damage/inflammation. For example, recent studies have determined that delta toxin is a potent inducer of mast cell degranulation (Nakamura ). Although IgE is not necessary for delta toxin-mediated mast cell degranulation, the presence of this allergy-associated antibody on mast cell results in exaggerated toxin responses (Nakamura ). Thus, AD patients with high levels of IgE in response to Th2 cytokine overactivity would be especially susceptible to delta toxin-mediated effects. Staphylococcal alpha toxin is one of the most prominent and destructive cytolytic toxins. This pore-forming toxin can act on cell membranes directly, and this process appears to be facilitated via binding to membrane sphingomyelin molecules. Alpha toxin treatment of keratinocytes induces cytokine production as well as inducing cellular death (Ezepchuk ; Travers ). As reported in this issue, Brauweiler and colleagues provide evidence that Th2 cytokine exposure can increase the sensitivity of keratinocytes to alpha toxin-mediated cell death (Brauweiler ). Alpha toxin treatment of skin biopsies derived from AD patients resulted in increased levels of cell death in comparison with normal skin. The role of Th2 cytokines was then confirmed using keratinocyte primary cultures treated with IL-4/IL-13. In contrast, gamma-interferon treatment did not modulate alpha toxin-mediated cytotoxicity. IL-4/IL-13 augmentation of alpha toxin-mediated cytotoxicity was shown to be due to the ability of these Th2 cytokines to decrease levels of acid sphingomyelinase, the enzyme that cleaves sphingomyelin into ceramide and phosphocholine. The ability of exogenous sphingomyelinase or phosphocholine to reverse the alpha toxin toxicity not only confirmed the mechanisms, but, also provided the rationale for possible therapeutics. The authors also demonstrated in a recent companion report that the epidermal barrier protein filaggrin also plays an important role in the regulation of acid sphingomyelinase, and that deficiency inf filaggrin predisposes for increased alpha toxin-mediated cytotoxicity (Brauweiler ). Relevant to Th2 cytokines, IL-4 and IL-13 have also been shown to inhibit filaggrin expression (Howell ). Thus, one can envision a positive feedback pathway by which Th2 cytokines not only provide a permissive environment for S. aureus, but, also enhance the effects of staphylococcal products. These findings are compatible with the notion that strategies that remove bacteria such as dilute bleach baths can improve AD skin disease (Huang ). In summary, the interplay between Th2 cytokines and S. aureus has high significance for understanding AD. Indeed, the majority of AD flares involve S. aureus in some capacity. New insights into the exact mechanisms by which staphylococcal exposure can worsen AD could allow improved and novel treatments for this common skin disease and its significant morbidities.
  8 in total

1.  Oral vitamin D modulates the epidermal expression of the vitamin D receptor and cathelicidin in children with atopic dermatitis.

Authors:  Carolina Cabalín; Guillermo Pérez-Mateluna; Carolina Iturriaga; Carlos A Camargo; Arturo Borzutzky
Journal:  Arch Dermatol Res       Date:  2022-10-22       Impact factor: 3.033

Review 2.  Staphylococcal Biofilms in Atopic Dermatitis.

Authors:  Tammy Gonzalez; Jocelyn M Biagini Myers; Andrew B Herr; Gurjit K Khurana Hershey
Journal:  Curr Allergy Asthma Rep       Date:  2017-10-23       Impact factor: 4.806

Review 3.  The Pathogenetic Effect of Natural and Bacterial Toxins on Atopic Dermatitis.

Authors:  Kyung-Duck Park; Sok Cheon Pak; Kwan-Kyu Park
Journal:  Toxins (Basel)       Date:  2016-12-23       Impact factor: 4.546

4.  Atopic dermatitis and autoimmunity: the occurrence of autoantibodies and their association with disease severity.

Authors:  James Holmes; Lucy C Fairclough; Ian Todd
Journal:  Arch Dermatol Res       Date:  2019-02-23       Impact factor: 3.017

Review 5.  Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review.

Authors:  Peck Y Ong; Donald Y M Leung
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 10.817

6.  Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial).

Authors:  Joan Totté; Jill de Wit; Luba Pardo; Frank Schuren; Martijn van Doorn; Suzanne Pasmans
Journal:  Trials       Date:  2017-08-31       Impact factor: 2.279

Review 7.  Interactions of the Skin Pathogen Haemophilus ducreyi With the Human Host.

Authors:  Julie A Brothwell; Brad Griesenauer; Li Chen; Stanley M Spinola
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561

8.  The Skin and Nose Microbiome and Its Association with Filaggrin Gene Mutations in Pediatric Atopic Dermatitis.

Authors:  Minke M F van Mierlo; Luba M Pardo; Karin B Fieten; Tim J van den Broek; Frank H J Schuren; Michel van Geel; Suzanne G M A Pasmans
Journal:  Dermatology       Date:  2022-01-18       Impact factor: 5.197

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.